Therapeutics News and Research

RSS

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Exosomes provide a promising way to induce human stem cell differentiation

Regenerative medicine using stem cells is an increasingly promising approach to treat many types of injury. Transplanted stem cells can differentiate into just about any other kind of cell, including neurons to potentially reconnect a severed spinal cord and repair paralysis.

16 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

NUS researchers develop new technique to observe nano-bio interactions

Researchers at the National University of Singapore have developed a technique to observe, in real time, how individual blood components interact and modify advanced nanoparticle therapeutics.

16 Sep 2015

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.

16 Sep 2015

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.

15 Sep 2015

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.

15 Sep 2015

Mitral valve disease patients enrolled in Harpoon’s Early Feasibility Study with 100% procedural success

Harpoon Medical, a medical device company focused on minimally-invasive, beating-heart, mitral valve repair, announced today that ten patients with severe degenerative mitral valve disease are now enrolled in its ongoing Early Feasibility Study at two clinical study sites in Europe.

15 Sep 2015

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

A US-Ireland partnership involving researchers at Queen's University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.

14 Sep 2015

Two St. Louis institutions collaborate to create Center for Clinical Pharmacology

St. Louis College of Pharmacy and Washington University School of Medicine in St. Louis are joining forces to find better, safer and more effective ways to use prescription medications to improve health. Researchers from the two institutions are collaborating to create the Center for Clinical Pharmacology.

14 Sep 2015

Future of transplant medicine to be explored during LifeNet Health Institute of Regenerative Medicine symposium

The LifeNet Health Institute of Regenerative Medicine is bringing together scientists and surgeons from around the world to explore the future of transplant medicine during its Scientific Symposium Sept. 25-26.

14 Sep 2015

Caltech researchers find antibody that can detect, neutralize HIV viruses in infected patients

Proteins called broadly neutralizing antibodies (bNAbs) are a promising key to the prevention of infection by HIV, the virus that causes AIDS. bNAbs have been found in blood samples from some HIV patients whose immune systems can naturally control the infection.

14 Sep 2015

Genetic mutations in deadly Ebola virus appear to block antibody-based treatments

Genetic mutations called "escape variants" in the deadly Ebola virus appear to block the ability of antibody-based treatments to ward off infection, according to a team of U.S. Army scientists and collaborators. Their findings, published online this week in the journal Cell Reports, have implications for the continued development of therapeutics to treat Ebola virus disease, which has claimed the lives of over 11,000 people in West Africa since last year.

14 Sep 2015

Researchers identify new epigenetic markers for colorectal cancer

Researchers at Nanjing University, China, found new epigenetic markers for colorectal cancer which may offer a new approach for treatment.

14 Sep 2015

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.

11 Sep 2015

BerGenBio honored with Nordic Stars Award for innovation in Nordic life science community

BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that it has been awarded one of this year's Nordic Stars Awards at the Nordic Life Science Days 2015 conference held in Stockholm, Sweden on 9-10 September, 2015.

11 Sep 2015

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

The American College of Rheumatology (ACR) has released two new publications - recommendations aimed at improving the treatment of patients with polymyalgia rheumatica (PMR), and new classification criteria for gout.

10 Sep 2015

Northwestern University nanoscientist wins Raymond and Beverly Sackler Prize in Convergence Research

Northwestern University scientist Chad A. Mirkin, one of the world's leaders in nanotechnology research and its application, has been awarded the inaugural $400,000 Raymond and Beverly Sackler Prize in Convergence Research from the National Academy of Sciences.

10 Sep 2015

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the first patient has been dosed in a newly initiated long term-safety extension study of Resolaris for adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

Therapeutics News and Research

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Exosomes provide a promising way to induce human stem cell differentiation

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

NUS researchers develop new technique to observe nano-bio interactions

Immune Pharmaceuticals’ CEO establishes stock trading plan

AgeneBio's HOPE4MCI Phase 3 trial receives support from NIH

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Mitral valve disease patients enrolled in Harpoon’s Early Feasibility Study with 100% procedural success

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

Two St. Louis institutions collaborate to create Center for Clinical Pharmacology

Future of transplant medicine to be explored during LifeNet Health Institute of Regenerative Medicine symposium

Caltech researchers find antibody that can detect, neutralize HIV viruses in infected patients

Genetic mutations in deadly Ebola virus appear to block antibody-based treatments

Researchers identify new epigenetic markers for colorectal cancer

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

BerGenBio honored with Nordic Stars Award for innovation in Nordic life science community

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

Northwestern University nanoscientist wins Raymond and Beverly Sackler Prize in Convergence Research

First patient dosed in long term-safety extension study of Resolaris for adult patients with FSHD

CureVac announces official launch of U.S. operations in Cambridge, MA

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News